In terms of drug resistance, further studies have revealed that LOXL3 promotes chemoresistance in liver cancer by stabilizing dihydroorotate dehydrogenase (DHODH) through activation of the intramitochondrial adenylate kinase 2 (AK2)-LOXL3-DHODH pathway, thereby inhibiting mitochondrial ferroptosis. Here, DHODH is linked to liver cancer.